Biofrontera Statistics
Total Valuation
Biofrontera has a market cap or net worth of $8.62 million. The enterprise value is $10.10 million.
Important Dates
The last earnings date was Wednesday, November 12, 2025, after market close.
| Earnings Date | Nov 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biofrontera has 11.65 million shares outstanding. The number of shares has increased by 119.81% in one year.
| Current Share Class | 11.65M |
| Shares Outstanding | 11.65M |
| Shares Change (YoY) | +119.81% |
| Shares Change (QoQ) | +15.24% |
| Owned by Insiders (%) | 9.42% |
| Owned by Institutions (%) | 15.47% |
| Float | 9.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.18 |
| Forward PS | 0.20 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.27 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15
| Current Ratio | 1.15 |
| Quick Ratio | 0.51 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -39.86 |
Financial Efficiency
Return on equity (ROE) is -1,191.73% and return on invested capital (ROIC) is -248.91%.
| Return on Equity (ROE) | -1,191.73% |
| Return on Assets (ROA) | -64.91% |
| Return on Invested Capital (ROIC) | -248.91% |
| Return on Capital Employed (ROCE) | -615.62% |
| Revenue Per Employee | $399,613 |
| Profits Per Employee | -$188,946 |
| Employee Count | 93 |
| Asset Turnover | 2.19 |
| Inventory Turnover | 2.44 |
Taxes
In the past 12 months, Biofrontera has paid $22,000 in taxes.
| Income Tax | 22,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.14% in the last 52 weeks. The beta is 0.56, so Biofrontera's price volatility has been lower than the market average.
| Beta (5Y) | 0.56 |
| 52-Week Price Change | -5.14% |
| 50-Day Moving Average | 0.98 |
| 200-Day Moving Average | 0.87 |
| Relative Strength Index (RSI) | 30.29 |
| Average Volume (20 Days) | 204,746 |
Short Selling Information
The latest short interest is 75,071, so 0.64% of the outstanding shares have been sold short.
| Short Interest | 75,071 |
| Short Previous Month | 66,545 |
| Short % of Shares Out | 0.64% |
| Short % of Float | 0.82% |
| Short Ratio (days to cover) | 0.79 |
Income Statement
In the last 12 months, Biofrontera had revenue of $37.16 million and -$17.57 million in losses. Loss per share was -$1.92.
| Revenue | 37.16M |
| Gross Profit | 23.94M |
| Operating Income | -17.62M |
| Pretax Income | -17.55M |
| Net Income | -17.57M |
| EBITDA | -17.51M |
| EBIT | -17.62M |
| Loss Per Share | -$1.92 |
Full Income StatementBalance Sheet
The company has $3.43 million in cash and $4.91 million in debt, giving a net cash position of -$1.48 million or -$0.13 per share.
| Cash & Cash Equivalents | 3.43M |
| Total Debt | 4.91M |
| Net Cash | -1.48M |
| Net Cash Per Share | -$0.13 |
| Equity (Book Value) | -2.58M |
| Book Value Per Share | -0.22 |
| Working Capital | 1.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$12.00 million and capital expenditures -$4,000, giving a free cash flow of -$12.01 million.
| Operating Cash Flow | -12.00M |
| Capital Expenditures | -4,000 |
| Free Cash Flow | -12.01M |
| FCF Per Share | -$1.03 |
Full Cash Flow StatementMargins
Gross margin is 64.41%, with operating and profit margins of -47.41% and -47.28%.
| Gross Margin | 64.41% |
| Operating Margin | -47.41% |
| Pretax Margin | -47.22% |
| Profit Margin | -47.28% |
| EBITDA Margin | -47.11% |
| EBIT Margin | -47.41% |
| FCF Margin | n/a |
Dividends & Yields
Biofrontera does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -119.81% |
| Shareholder Yield | -119.81% |
| Earnings Yield | -203.91% |
| FCF Yield | -139.32% |
Analyst Forecast
The average price target for Biofrontera is $2.75, which is 271.72% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.75 |
| Price Target Difference | 271.72% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 23.82% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 5, 2023. It was a reverse split with a ratio of 1:20.
| Last Split Date | Jul 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Biofrontera has an Altman Z-Score of -13.1 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.1 |
| Piotroski F-Score | 3 |
